Regional changes in [ 18 F]dopa metabolism in the striatum in Parkinson's disease

We have investigated regional changes in dopamine metabolism within the basal ganglia with clinical progression of idiopathic Parkinson's disease, using coregistration of [F]dopa-PET and MRI images and comparing six normal subjects with 15 Parkinson's disease patients in a crosssectional study. We have demonstrated that [F]dopa metabolism in the dorsal putamen is reduced to almost 50% of normal both caudally and rostrally early in the disease whilst the ventral putamen is not significantly affected. With progression of symptoms there is loss of dopa metabolism from the ventral putamen, the ventrocaudal putamen in advance of the ventrorostral putamen. Throughout the disease the ventrorostral putamen is relatively preserved; even in the most advanced group [F]dopa uptake is reduced here by only 30%. We conclude that the progression of Parkinson's disease is associated with a focal process affecting only the dorsal putamen in its early (and preclinical) phase then affecting the ventral putamen with increasing disease severity.

[1]  Richard S. J. Frackowiak,et al.  Striatal function in normal aging: Implications for Parkinson's disease , 1990, Annals of neurology.

[2]  J. Mazziotta,et al.  Rapid Automated Algorithm for Aligning and Reslicing PET Images , 1992, Journal of computer assisted tomography.

[3]  H. Kimura,et al.  Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.

[4]  Y. Agid,et al.  Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.

[5]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[6]  V. Dhawan,et al.  Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[8]  B. Kollmeier,et al.  Parkinson's disease: progression and mortality in the L-DOPA era. , 1996, Advances in neurology.

[9]  P. Cumming,et al.  Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. , 1986, Life sciences.

[10]  Vincent Frouin,et al.  Clinical correlates of {18F}fluorodopa uptake in five grafted Parkinsonian patients , 1995, Annals of neurology.

[11]  D B Calne,et al.  Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.

[12]  K. Herholz,et al.  Discordant twins with Parkinson's disease: Positron emission tomography and early signs of impaired cognitive circuits , 1994, Annals of neurology.

[13]  A. E. Harding,et al.  Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography , 1992, Neurology.

[14]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[15]  C D Marsden,et al.  The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. , 1990, Brain : a journal of neurology.

[16]  R A Robb,et al.  A software system for interactive and quantitative visualization of multidimensional biomedical images. , 1991, Australasian physical & engineering sciences in medicine.

[17]  J. Holden,et al.  Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  F. Vingerhoets,et al.  Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease , 1995, Annals of neurology.

[19]  G. Sawle,et al.  Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. , 1994, Archives of neurology.

[20]  D J Brooks,et al.  An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.

[21]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[22]  Richard S. J. Frackowiak,et al.  Transplantation of fetal dopamine neurons in Parkinson's disease: One‐year clinical and neurophysiological observations in two patients with putaminal implants , 1992, Annals of neurology.

[23]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[24]  J. Haycock,et al.  Striatal 3,4‐dihydroxyphenylalanine decarboxylase in aging: Disparity between postmortem and positron emission tomography studies? , 1995, Annals of neurology.

[25]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .